Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.45 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.45 |
| ▸ | CBX7 | O95931 | 1/20 | 0.43 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 6/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5675223 | 0.86 | GAA (0.43) | KMT2ACBX7CDYLIDO1MGAM | |
| SCHEMBL5675888 | 0.85 | ADAMTS5 (0.47) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL1795899 | 0.83 | KMT2A (0.51) | KMT2AKCNQ3KCNQ2KCNQ4KCNMA1 | |
| SCHEMBL7470395 | 0.82 | IDO1 (0.45) | KMT2AIDO1MGAMHTR1AGAA | |
| SCHEMBL5678369 | 0.82 | KMT2A (0.45) | KMT2AKCNQ3KCNQ2KCNQ4KCNMA1 | |
| SCHEMBL7470907 | 0.82 | AKR1C3 (0.47) | KMT2AIDO1MGAMHTR1AGAA | |
| SCHEMBL1464565 | 0.82 | KMT2A (0.72) | KMT2AKCNQ3KCNQ2KCNQ4KCNMA1 | |
| SCHEMBL27494161 | 0.80 | KMT2A (0.48) | KMT2AKCNQ3KCNQ2KCNQ4KCNMA1 | |
| SCHEMBL27510705 | 0.79 | IDO1 (0.42) | KMT2ACBX7CDYLIDO1MGAM | |
| SCHEMBL4590061 | 0.78 | CBX7 (0.47) | KMT2AKCNQ3KCNQ2KCNQ4KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338590-B2 | Substituted oxindole derivatives and medicaments containing the same | ABBOTT GMBH & CO. KG (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20110257194-A1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | ABBOTT GMBH & CO. KG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-7951807-B2 | Substituted oxindol derivatives and medicaments containing the same | ABBOTT GMBH & CO. KG (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20090005397-A1 | Substituted Oxindol Derivatives and Medicaments Containing the Same | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1773814-B1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | ABBOTT GMBH & CO KG (DE) | 2007-11-07 | — | — | EP | disclosed |
| EP-1773814-A2 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | Abbott GmbH & Co. KG (DE) | 2007-04-18 | — | — | EP | disclosed |
| US-7119086-B2 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | disclosed |
| WO-2006005609-A2 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | ABBOTT GMBH & CO.KG (DE) | 2006-01-19 | — | — | WO | disclosed |
| EP-1419150-B1 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2005-04-27 | — | — | EP | disclosed |
| CN-1533387-A | 1-phenysulfonyl-1,3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use | ����ɳŵ��-����������˾ | 2004-09-29 | — | — | CN | disclosed |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
| EP-1419150-A2 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003008407-A2 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-SYNTHELABO (FR) | 2003-01-30 | — | — | WO | disclosed |
| EP-0687251-B1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI SYNTHELABO (FR) | 2002-02-27 | — | — | EP | disclosed |
| US-5773612-A | VASOPRESSIN OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5594023-A | 1,3-dihydroindol-2-one derivatives substituted in the 3-position by a nitrogen-containing group, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-01-14 | — | — | US | disclosed |
| EP-0687251-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995018105-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005397-A1 | Substituted Oxindol Derivatives and Medicaments Containing the Same | OXTR, AVPR2, AVPR1B | KMT2A 4350/4885KCNQ3 843/4885KCNQ2 1168/4885 |
| US-20110257194-A1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | OXTR, AVPR2, AVPR1B | KMT2A 4284/4885KCNQ3 1014/4885KCNQ2 1330/4885 |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | KMT2A 1662/4885KCNQ3 1426/4885KCNQ2 964/4885 |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | AVPR2, AVPR1A, AVPR1B | KMT2A 4309/4885KCNQ3 912/4885KCNQ2 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.